Patent · US Active

SDF-1 binding nucleic acids and the use thereof in cancer treatment

US9387221B2 · kind B2 · utility

2Cited by

8References

20Claims

0Family size

Assignee

NOXXON Pharma AG · DE

Inventors

Werner Purschke · Berlin, DE
Florian Jarosch · Berlin, DE
Dirk Eulberg · Berlin, DE
Sven Klussmann · Berlin, DE
Klaus Buchner · Schaffhausen, CH
Christian Maasch · Berlin, DE
Nicole Dinse · Berlin, DE
Dirk Zboralski · Berlin, DE

Key dates

Filing date	Nov 20, 2015
Grant date	Jul 12, 2016
Priority date	—
Expiry date	Nov 20, 2035

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2320/31
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention is related to a nucleic acid molecule capable of binding to SDF-1, preferably capable of inhibiting SDF-1, whereby the nucleic acid molecule is for use in a method for the treatment and/or prevention of a disease or disorder, for use in a method for the treatment of a subject suffering from a disease or disorder or being at risk of developing a disease or disorder as an adjunct therapy, or for use as a medicament for the treatment and/or prevention of a disease or disorder, whereby the disease or disorder is cancer.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.